T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
β Scribed by Bernd Schlereth; Cornelia Quadt; Torsten Dreier; Peter Kufer; Grit Lorenczewski; Nadja Prang; Christian Brandl; Sandra Lippold; Kathy Cobb; Kathleen Brasky; Eugen Leo; Ralf Bargou; Krishna Murthy; Patrick A. Baeuerle
- Book ID
- 105966883
- Publisher
- Springer-Verlag
- Year
- 2005
- Tongue
- English
- Weight
- 412 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Certain bispecific antibodies exhibit an extraordinary potency and efficacy for target cell lysis by eliciting a polyclonal Tβcell response. One example is a CD19β/CD3βbispecific singleβchain antibody construct (bscCD19xCD3), which at femtomolar concentrations can redirect cytotoxic T c
## Anti -CD3 Ψ anti-B-cell antigen bispecific monoclonal antibodies (bsAbs) can redirect T-cell-mediated lysis toward malignant B cells. Clinical trials with CD3-based bsAbs have shown toxicity in patients which is likely related to nonspecific T-cell activation and targeting. Our current studies